Cargando…
A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction
PURPOSE: A model for predicting the prognosis of patients with heart failure with reduced left ventricular ejection fraction (HFrEF) is currently not available. This study aimed to develop an age-biomarker-clinical history prognostic index (ABC-PI) and validate it for the assessment of individual pr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712124/ https://www.ncbi.nlm.nih.gov/pubmed/33336021 http://dx.doi.org/10.1515/med-2020-0209 |
_version_ | 1783618300995960832 |
---|---|
author | Li, Hao Cui, Yuan Tian, Jin Yang, Hong Zhang, Qing Wang, Ke Han, Qinghua Zhang, Yanbo |
author_facet | Li, Hao Cui, Yuan Tian, Jin Yang, Hong Zhang, Qing Wang, Ke Han, Qinghua Zhang, Yanbo |
author_sort | Li, Hao |
collection | PubMed |
description | PURPOSE: A model for predicting the prognosis of patients with heart failure with reduced left ventricular ejection fraction (HFrEF) is currently not available. This study aimed to develop an age-biomarker-clinical history prognostic index (ABC-PI) and validate it for the assessment of individual prognosis. PATIENTS AND METHODS: A total of 5,974 HFrEF patients were enrolled and 1,529 were included in this study after excluding missing values and loss to follow-up. Variables that significantly contributed to prediction of all-cause mortality were assessed by Cox regression and latent trait analysis (LTA) was used to validate discrimination of variables. RESULTS: After Cox regression, the following seven most significant variables were selected: age, N-terminal pro-B-type natriuretic peptide, renal dysfunction, left ventricular mass index, percutaneous coronary intervention, atrial fibrillation, and New York Heart Association (C-index: 0.801 ± 0.013). After verification by LTA, discrimination of these seven variables was proven. A nomogram was used to form the ABC-PI, and then the total score was set to 100 points. A lower score indicated a higher risk. After verification, the 3-year mortality rate was 34.7% in the high-risk group and only 2.6% in the low-risk group. CONCLUSION: Our novel ABC-PI shows a good performance and does not require re-input in the original model. The ABC-PI can be used to effectively and practically predict the prognosis of HFrEF patients. |
format | Online Article Text |
id | pubmed-7712124 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | De Gruyter |
record_format | MEDLINE/PubMed |
spelling | pubmed-77121242020-12-16 A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction Li, Hao Cui, Yuan Tian, Jin Yang, Hong Zhang, Qing Wang, Ke Han, Qinghua Zhang, Yanbo Open Med (Wars) Research Article PURPOSE: A model for predicting the prognosis of patients with heart failure with reduced left ventricular ejection fraction (HFrEF) is currently not available. This study aimed to develop an age-biomarker-clinical history prognostic index (ABC-PI) and validate it for the assessment of individual prognosis. PATIENTS AND METHODS: A total of 5,974 HFrEF patients were enrolled and 1,529 were included in this study after excluding missing values and loss to follow-up. Variables that significantly contributed to prediction of all-cause mortality were assessed by Cox regression and latent trait analysis (LTA) was used to validate discrimination of variables. RESULTS: After Cox regression, the following seven most significant variables were selected: age, N-terminal pro-B-type natriuretic peptide, renal dysfunction, left ventricular mass index, percutaneous coronary intervention, atrial fibrillation, and New York Heart Association (C-index: 0.801 ± 0.013). After verification by LTA, discrimination of these seven variables was proven. A nomogram was used to form the ABC-PI, and then the total score was set to 100 points. A lower score indicated a higher risk. After verification, the 3-year mortality rate was 34.7% in the high-risk group and only 2.6% in the low-risk group. CONCLUSION: Our novel ABC-PI shows a good performance and does not require re-input in the original model. The ABC-PI can be used to effectively and practically predict the prognosis of HFrEF patients. De Gruyter 2020-07-10 /pmc/articles/PMC7712124/ /pubmed/33336021 http://dx.doi.org/10.1515/med-2020-0209 Text en © 2020 Hao Li et al., published by De Gruyter http://creativecommons.org/licenses/by/4.0 This work is licensed under the Creative Commons Attribution 4.0 International License. |
spellingShingle | Research Article Li, Hao Cui, Yuan Tian, Jin Yang, Hong Zhang, Qing Wang, Ke Han, Qinghua Zhang, Yanbo A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction |
title | A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction |
title_full | A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction |
title_fullStr | A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction |
title_full_unstemmed | A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction |
title_short | A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction |
title_sort | novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712124/ https://www.ncbi.nlm.nih.gov/pubmed/33336021 http://dx.doi.org/10.1515/med-2020-0209 |
work_keys_str_mv | AT lihao anovelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction AT cuiyuan anovelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction AT tianjin anovelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction AT yanghong anovelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction AT zhangqing anovelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction AT wangke anovelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction AT hanqinghua anovelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction AT zhangyanbo anovelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction AT lihao novelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction AT cuiyuan novelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction AT tianjin novelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction AT yanghong novelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction AT zhangqing novelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction AT wangke novelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction AT hanqinghua novelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction AT zhangyanbo novelagebiomarkerclinicalhistoryprognosticindexforheartfailurewithreducedleftventricularejectionfraction |